Clinical Trial Update: Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating Nafamostat Mesilate for severe infection-associated coagulopathy related to sepsis and sepsis-induced coagulopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Sepsis-induced Coagulopathy

Drugs mentioned

• Nafamostat Mesilate (Nafamostat mesilate)

Snippet

Sponsor: Xu Li | Conditions: Sepsis, Sepsis-induced Coagulopathy | Phase 4 | Status: NOT_YET_RECRUITING